Pyrimidine derivatives and methods of making and using these derivatives

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 54
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z2 and Z3 are different and are selected from the group consisting of R4 and
• 55
• where Z2 is R4 when Z3 is
• 56
• and Z2 is
• 57
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of CH, nitrogen, N—CH2, CH2—N, CH2—CH2, oxygen and sulfur;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is oxygen or sulfur;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R5 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R8 is selected from the group consisting of naphthyl, mono-, di- and tri-substituted naphthyl, thionaphthyl, thiophenyl and hydroxyphenyl when R1 is hydrogen and R4 is hydrogen;
• wherein R8 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl, pyridine and p-aroyl-L-glutamate when R1 is a lower alkyl group and R4 is hydrogen;
• wherein R8 is selected from the group consisting of pyridine, phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl and p-aroyl-L-glutamate when R1 is zero;
• wherein R8 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl and p-aroyl-L-glutamate when R1 is hydrogen and R4 is a lower alkyl group;
• wherein R8 is not p-benzoyl-L-glutamate or pyridine when X is OH, A is zero, B is sulfur, R4 is methyl and R5 is hydrogen, and R8 is not p-benzoyl-L-glutamate when X is OH, A is CH, B is CH, R4 is hydrogen and R5 is hydrogen;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 58
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z2 and Z3 are different and are selected from the group consisting of R4 and
• 59
• where Z1 is R4 when Z3 is
• 60
• and Z2 is
• 61
• when Z3 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of CH, nitrogen, N—CH2, CH2—N, CH2—CH2,oxygen and sulfur;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is oxygen or sulfur;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R5 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R8 is selected from the group consisting of naphthyl, mono-, di- and tri-substituted-naphthyl, thionaphthyl, thiophenyl and hydroxyphenyl when R1 is hydrogen and R4 is hydrogen;
• wherein R8 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl, pyridine and p-aroyl-L-glutamate when R1 is a lower alkyl group and R4 is hydrogen;
• wherein R8 is selected from the group consisting of pyridine, phenyl, mono-, di- and tri,-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl and p-aroyl-L-glutamate when R1 is zero;
• wherein R8 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl and p-aroyl-L-glutamate when R1 is hydrogen and R4 is a lower alkyl group;
• wherein R8 is not p-benzoyl-L-glutamate or pyridine when X is OH, A is zero, B is sulfur, R4 is methyl and R5 is hydrogen, and R8 is not p-benzoyl-L-glutamate when X is OH, A is CH, B is CH, R4 is hydrogen and R5 is hydrogen;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

A method of synthesizing a compound, and pharmaceutically acceptable salts thereof, having the formula:

• 62
• wherein R is selected from the group consisting of a lower alkyl group, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having-from about 1 to 6 carbons, comprising the steps of:
• a) debrominating a pyrrole;
• b) fusing the product of step a) with an amidine;
• c) condensing the product of step b) with a nucleophile;
• d) reducing the product of step c);
• and
• e) purifying the compounds of step d).

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, an pharmaceutically acceptable salts thereof, having the formula:
• 64
• wherein R is selected from the group consisting of a lower alkyl group, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is-the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a-halogen, wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• which has been synthesized by the steps comprising:
• i) debrominating a pyrrole;
• ii) fusing the product of step a) with an amidine;
• iii) condensing the product of step b) with a nucleophile;
• iv) reducing the product of step c);
• and
• v) purifying the compounds of step d);
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 65
• wherein R is selected from the group consisting of a lower alkyl group,, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen, wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• which has been synthesized by the steps comprising:
• i) debrominating a pyrrole;
• ii) fusing the product of step a) with an amidine;
• iii) condensing the product of step b) with a nucleophile;
• iv) reducing the product of step c);
• and
• v) purifying the compounds of step d).
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

A compound, and pharmaceutically acceptable salts thereof, having the formula:

• 66
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 67
• where Z is R4 when Z1 is
• 68
• and Z is
• 69
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted-alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl, an alkoxy, an alkoxyaryloxy group, a halogen and zero but R2 is not 3,4,5-trimethoxyphenyl, 3,4,5-trichlorophenyl, 3,4-dichlorophenyl, 2,5-dimethoxyphenyl or a p-benzoyl-L-glutamate when R1 is hydrogen and R4 is hydrogen, and R2 is not p-benzoyl-L-glutamate when R1 is methyl;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group, and zero and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen, a lower alkyl group and S—R7 where R7 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl and p-aroyl-L-glutamate;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from 1 to 6 carbons.

A method of synthesizing a compound, and pharmaceutically acceptable salts thereof, having the formula:

• 70
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 71
• where Z is R4 when Z1 is
• 72
• and Z is
• 73
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or,,the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero, but R2 is not 3,4,5-trimethoxyphenyl, 3,4,5-trichlorophenyl, 3,4-dichlorophenyl, 2,5-dimethoxyphenyl or p-benzoyl-L-glutamate when R1 is hydrogen and R4 is hydrogen, and R2 is not p-benzoyl-L-glutamate when R1 is methyl;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group, and zero and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen, a lower alkyl group and S—R7 where R7 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl and p-aroyl-L-glutamate,;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from 1 to 6 carbons, comprising the steps of:
• a) stirring a pyrimidine and a substituted acetone in a solvent;
• b) purifying the product of step a);
• c) performing nucleophilic displacement of the chloride in the product of step b);
• and
• d) purifying the product of step c).

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 75
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z, are different and are selected from the group consisting of R4 and
• 76
• where Z is R4 when Z1 is
• 77
• and Z is
• 78
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero, but R2 is not 3,4,5-trimethoxyphenyl, 3,4,5-trichlorophenyl, 3,4-dichlorophenyl, 2,5-dimethoxyphenyl or p-benzoyl-L-glutamate when R1 is hydrogen and R4 is hydrogen, and R2 is not p-benzoyl-L-glutamate when R1 is methyl;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group, and zero and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen, a lower alkyl group and S—R7 where R7 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl and p-aroyl-L-glutamate;
• and
• wherein each-lower alkyl group is independently selected from the group consisting of lower alkyl groups having from 1 to 6 carbons, and is synthesized by the steps:
• i) stirring a pyrimidine and a substituted acetone in a solvent;
• ii) purifying the product of step a);
• iii) performing nucleophilic displacement of the chloride in the product of step b);
• and
• iv) purifying the product of step c);
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a-compound, or pharmaceutically acceptable salts thereof, having the formula:
• 79
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the-group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 80
• where Z is R4 when Z1 is
• 81
• and Z is
• 82
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero, but R2 is not 3,4,5-trimethoxyphenyl, 3,4,5-trichlorophenyl, 3,4-dichlorophenyl, 2,5-dimethoxyphenyl or p-benzoyl-L-glutamate when R1 is hydrogen and R4 is hydrogen, and R2 is not p-benzoyl-L-glutamate when R1 is methyl;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group, and zero and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen, a lower alkyl group and S—R7 where R7 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl, and p-aroyl-L-glutamate;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from 1 to 6 carbons, and is synthesized by the steps:
• i) stirring a pyrimidine and a substituted acetone in a solvent;
• ii) purifying the product of step a);
• iii) performing nucleophilic displacement of the chloride in the product of step b);
• and
• iv) purifying the product of step c);
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

The compound, and pharmaceutically acceptable salts thereof, having the formula:

• 83
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 84
• where Z is R4 when Z1 is
• 85
• and Z is
• 86
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, an aryl group, p-aroyl-L-glutamate, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons.

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 87
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 88
• where Z is R4 when Z1 is
• 89
• and Z is
• 90
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 91
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 92
• where Z is R4 when Z1 is
• 93
• and Z is
• 94
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group, and zero and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

A compound, and pharmaceutically acceptable salts thereof, having the formula:

• 95
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH,;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 96
• where Z is R4 when Z1 is
• 97
• and Z is
• 98
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero, and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and lower alkyl group;
• wherein R5 is selected from the group consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons.

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 99
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 100
• where Z is R4 when Z1 is
• 101
• and Z is
• 102
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero, and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and lower alkyl group;
• wherein R5 is selected from the group consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 103
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 104
• where Z is R4 when Z1 is
• 105
• and Z is
• 106
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero, and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zerom, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and lower alkyl group;
• wherein R5 is selected from the group consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

A compound, and pharmaceutically acceptable salts thereof, having the formula:

• 107
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group, and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group ,consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons.

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 108
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 109
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group,-p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and lower alkyl group;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

A compound, and pharmaceutically acceptable salts thereof, having the formula:

• 110
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z4, Z5 and Z6 are different and are selected from the group consisting of R4, R5 and
• 111
• wherein A is selected from the group consisting of CH, sulfur and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero, and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl, group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R5 is selected from the group consisting of hydrogen and a lower alkyl group;
• where R4 is the same or different than R5;
• wherein each of said R4, R5 and
• 112
• substituents is used once;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons.

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 113
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z4, Z5 and Z6 are different and are selected from the group consisting of R4, R5 and
• 114
• wherein A is selected from the group consisting of CH, sulfur and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero, and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group,:an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R5 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R4 is the same or different than R5;
• wherein each of said R4, R5 and
• 115
• substituents is used once;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 116
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z4, Z5 and Z6 are different and are selected from the group consisting of R4, R5 and
• 117
• wherein A is selected from the group consisting of CH, sulfur and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero, and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, or alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group and zero, and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R5 is selected from the group consisting of hydrogen and a lower alkyl group;
• wherein R4 is the same or different than R5;
• wherein each of said R4, R5 and
• 118
• substituents is used once;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, an pharmaceutically acceptable salts thereof, having the formula:
• 119
• wherein R is selected from the group consisting of a lower alkyl group, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen, wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 120
• wherein R is selected from the group consisting of a lower alkyl group, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen, wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from about 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering,a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 121
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 122
• where Z is R4 when Z1 is
• 123
• and Z is
• 124
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero, but R2 is not 3,4,5-trimethoxyphenyl, 3,4,5-trichlorophenyl, 3,4-dichlorophenyl, 2,5-dimethoxyphenyl or p-benzoyl-L-glutamate when R1 is hydrogen and R4 is hydrogen, and R2 is not p-benzoyl-L-glutamate when R1 is methyl;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group, and zero and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen, a lower alkyl group and S—R7 where R7 is selected from the group consisting of phenyl, mono-, di- and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl and p-aroyl-L-glutamate;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 125
• wherein X and Y are the same or different and are selected from the group consisting of OH and NH2;
• wherein L and M are selected from the group consisting of carbon and CH, the chemical bond between L and M is selected from the group consisting of a single bond and a double bond, L and M are carbon when the bond is a double bond, and L and M are CH when the bond is a single bond;
• wherein Z and Z1 are different and are selected from the group consisting of R4 and
• 126
• where Z is R4 when Z1 is
• 127
• and Z is
• 128
• when Z1 is R4;
• wherein A is selected from the group consisting of CH and zero;
• wherein B is selected from the group consisting of sulfur, nitrogen, oxygen, CH, N—CH2, CH2—N, CH2—CH2, and zero;
• wherein R1 is selected from the group consisting of hydrogen, a lower alkyl group, a nitroso group, a formyl group and zero and R1 is zero when B is sulfur, oxygen or zero;
• wherein R2 is selected from the group consisting of a lower alkyl group, p-aroyl-L-glutamate, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, an alkoxyaryloxy group, a halogen and zero, but R2 is not 3,4,5-trimethoxyphenyl, 3,4,5-trichlorophenyl, 3,4-dichlorophenyl, 2,5-dimethoxyphenyl or p-benzoyl-L-glutamate when R1 is hydrogen and R4 is hydrogen, and R2 is not p-benzoyl-L-glutamate when R1 is methyl;
• wherein R3 is selected from the group consisting of hydrogen, a lower alkyl group, and zero and R3 is zero when A is zero;
• wherein R4 is selected from the group consisting of hydrogen, a lower alkyl group and S—R7 where R7 is selected from the group consisting-of phenyl, mono-, di-,and tri-substituted phenyl, naphthyl, mono-, di- and tri-substituted naphthyl, and p-aroyl-L-glutamate;
• and
• wherein each lower alkyl group is independently selected from the group consisting of lower alkyl groups having from 1 to 6 carbons;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.

A method of synthesizing pyrrolo-[2,3-d]pyrimidine compounds, and pharmaceutically acceptable salts thereof, having the formula:

• 129
• wherein Q is selected from the group consisting of nitrogen and sulfur;
• wherein R is selected from the group consisting of a lower alkyl group, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• wherein R10 is selected from the group consisting of hydrogen and a lower alkyl group;
• and
• wherein R10 is a lower alkyl when Q is nitrogen, comprising the steps of:
• a) debrominating a pyrrole;
• b) fusing the product of step a) with an amide;
• c) condensing the product of step b) with a nucleophile;
• d) reducing the product of step c);
• and
• e) purifying the compounds of step d).

A compound, and pharmaceutically acceptable salts thereof, having the formula:

• 131
• wherein Q is selected from the group consisting of nitrogen and sulfur;
• wherein R is selected from the group consisting of a lower alkyl group, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• wherein R10 is selected from the group consisting of hydrogen and a lower alkyl group;
• and
• wherein R10 is a lower alkyl when Q is nitrogen.

A method of therapeutically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 132
• wherein Q is selected from the group consisting of nitrogen and sulfur;
• wherein R is selected from the group consisting of a lower alkyl group, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• wherein R10 is selected from the group consisting of hydrogen and a lower alkyl group;
• and
• wherein R10 is a lower alkyl when Q is nitrogen;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

A method of prophylactically treating a patient for an illness comprising the steps of:

• a) employing a compound, or pharmaceutically acceptable salts thereof, having the formula:
• 133
• wherein Q is selected from the group consisting of nitrogen and sulfur;
• wherein R is selected from the group consisting of a lower alkyl group, a p-aroyl-L-glutamate group, an aryl group, an alkylaryl group, a substituted aryl group, a substituted alkylaryl group, a diaryl group, a triaryl group, an alkyldiaryl group, an alicyclic hydrocarbon group, an alkyltriaryl group, a substituted diaryl group, and a substituted triaryl group, and each substituent of the substituted aryl group, diaryl group, triaryl group, or the substituted alkylaryl group, alkyldiaryl group, alkyltriaryl group is the same or different and is selected from the group consisting of a lower alkyl group, an alkoxy, a substituted alkoxyaryloxy group and a halogen;
• wherein R10 is selected from the group consisting of hydrogen and a lower alkyl group;
• and
• wherein R10 is a lower alkyl when Q is nitrogen;
• b) incorporating said compound in a suitable pharmaceutical carrier;
• and
• c) administering a prophylactically effective amount of said compound incorporated in said carrier to a patient;
• wherein said illness is selected from the group consisting of infection caused by Pneumocystis carinii and Toxoplasmosis gondii.